Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality

Jiri Parenica, Jan Malaska, Jiri Jarkovsky, Jolana Lipkova, Milan Dastych, Katerina Helanova, Jiri Litzman, Josef Tomandl, Simona Littnerova, Jana Sevcikova, Roman Gal, Pavel Sevcik, Jindrich Spinar, Monika Pavkova Goldbergova

. 2012 ; 17 (4) : 205-209.

Jazyk angličtina Země Kanada

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc13016224

Grantová podpora
NS9894 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Soluble ST2 (sST2) is an interleukin-33 receptor. sST2 was found to be an independent prognostic factor in patients with myocardial infarction, sepsis and heart failure. OBJECTIVES: To assess sST2 levels in patients with cardiogenic shock (CS) and septic shock (SS), and to evaluate the prognostic value of sST2 for short-term mortality. METHODS: The present prospective observational study evaluated 32 patients with CS, 17 patients with SS and 61 patients with ST segment elevation myocardial infarction (STEMI )(control group). Samples of serum were collected eight times and the follow-up time was three months. RESULTS: sST2 levels were elevated from admission in SS patients relative to patients with CS and STEMI, who exhibited peak sST2 levels 24 h after admission. On admission, CS patients had a median (5th percentile; 95th percentile) sST2 level of 62.5 pg/mL (8.3 pg/mL; 315.8 pg/mL) and SS patients had a median sST2 level of 216.4 pg/mL (46.8 pg/mL; 364.4 pg/mL). ROC analysis found sST2 to be a biomarker that could distinguish between CS and SS at admission (area under the curve [AUC] 0.813; P<0.01) with a cut-off value of 210.4 pg/mL. Patients with STEMI had significantly lower sST2 levels at admission (20.3 pg/mL (4.2 pg/mL; 339.8 pg/mL) compared with CS patients. The AUC of the ROC analysis was 0.671 (P=0.007) for the detection of CS in patients with STEMI. Only a weak correlation was observed between sST2 and B-type natriuretic peptide (r=0.376, P=0.05) and sST2 and N-terminal pro-B-type natriuretic peptide (r=0.496, P=0.019). No statistically significant differences were observed in sST2 levels in patients with CS and SS relative to three-month mortality. CONCLUSION: Levels of sST2 at admission are significantly higher in patients with SS compared with CS. sST2 could be a diagnostic marker to distinguish SS and CS as well as CS and STEMI at the time of admission. Levels of sST2 are related to levels of natriuretic peptides in CS but not in SS. sST2 levels are not a suitable prognostic marker for patients with CS and SS.

000      
00000naa a2200000 a 4500
001      
bmc13016224
003      
CZ-PrNML
005      
20140929102640.0
007      
ta
008      
130424s2012 xxc f 000 0|eng||
009      
AR
035    __
$a (PubMed)23592937
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxc
100    1_
$a Pařenica, Jiří $7 xx0101388 $u Department of Internal Cardiology Medicine, University Hospital Brno, Brno, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic; International Clinical Research Centre, Department of Cardiovascular Disease, University Hospital St Anne's, Brno, Czech Republic
245    10
$a Soluble ST2 levels in patients with cardiogenic and septic shock are not predictors of mortality / $c Jiri Parenica, Jan Malaska, Jiri Jarkovsky, Jolana Lipkova, Milan Dastych, Katerina Helanova, Jiri Litzman, Josef Tomandl, Simona Littnerova, Jana Sevcikova, Roman Gal, Pavel Sevcik, Jindrich Spinar, Monika Pavkova Goldbergova
520    9_
$a BACKGROUND: Soluble ST2 (sST2) is an interleukin-33 receptor. sST2 was found to be an independent prognostic factor in patients with myocardial infarction, sepsis and heart failure. OBJECTIVES: To assess sST2 levels in patients with cardiogenic shock (CS) and septic shock (SS), and to evaluate the prognostic value of sST2 for short-term mortality. METHODS: The present prospective observational study evaluated 32 patients with CS, 17 patients with SS and 61 patients with ST segment elevation myocardial infarction (STEMI )(control group). Samples of serum were collected eight times and the follow-up time was three months. RESULTS: sST2 levels were elevated from admission in SS patients relative to patients with CS and STEMI, who exhibited peak sST2 levels 24 h after admission. On admission, CS patients had a median (5th percentile; 95th percentile) sST2 level of 62.5 pg/mL (8.3 pg/mL; 315.8 pg/mL) and SS patients had a median sST2 level of 216.4 pg/mL (46.8 pg/mL; 364.4 pg/mL). ROC analysis found sST2 to be a biomarker that could distinguish between CS and SS at admission (area under the curve [AUC] 0.813; P<0.01) with a cut-off value of 210.4 pg/mL. Patients with STEMI had significantly lower sST2 levels at admission (20.3 pg/mL (4.2 pg/mL; 339.8 pg/mL) compared with CS patients. The AUC of the ROC analysis was 0.671 (P=0.007) for the detection of CS in patients with STEMI. Only a weak correlation was observed between sST2 and B-type natriuretic peptide (r=0.376, P=0.05) and sST2 and N-terminal pro-B-type natriuretic peptide (r=0.496, P=0.019). No statistically significant differences were observed in sST2 levels in patients with CS and SS relative to three-month mortality. CONCLUSION: Levels of sST2 at admission are significantly higher in patients with SS compared with CS. sST2 could be a diagnostic marker to distinguish SS and CS as well as CS and STEMI at the time of admission. Levels of sST2 are related to levels of natriuretic peptides in CS but not in SS. sST2 levels are not a suitable prognostic marker for patients with CS and SS.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Maláska, Jan, $d 1975- $7 stk2007393925 $u Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Anesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic
700    1_
$a Jarkovský, Jiří $7 stk2008461294 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Brno, Czech Republic
700    1#
$a Lipková, Jolana. $7 jo2007271778 $u Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Dastych, Milan, $d 1948- $7 mzk2007390652 $u Department of Biochemistry, University Hospital Brno, Brno, Czech Republic; Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1#
$a Helánová, Kateřina. $7 xx0185835 $u Department of Internal Cardiology Medicine, University Hospital Brno, Brno, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Litzman, Jiří, $7 xx0000488 $u Department of Clinical Immunology and Allergology, St Anne's University Hospital, Brno, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic $d 1958-
700    1_
$a Tomandl, Josef, $d 1964- $7 mzk2003175507 $u Department of Biochemistry, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1#
$a Littnerová, Simona. $7 jo2012694303 $u Institute of Biostatistics and Analyses, Faculty of Medicine, Brno, Czech Republic
700    1_
$a Ševčíková, Jana $u Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Gál, Roman $7 mzk2004265211 $u Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Anesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic
700    1_
$a Ševčík, Pavel, $d 1953- $7 mzk2003186005 $u Faculty of Medicine, Masaryk University, Brno, Czech Republic; Department of Anesthesiology and Intensive Care Medicine, University Hospital Brno, Brno, Czech Republic
700    1_
$a Špinar, Jindřich, $d 1960- $7 nlk20030128322 $u Department of Internal Cardiology Medicine, University Hospital Brno, Brno, Czech Republic; Faculty of Medicine, Masaryk University, Brno, Czech Republic; International Clinical Research Cente, Department of Cardiovascular Disease, University Hospital St Anne's, Brno, Czech Republic
700    1_
$a Pávková Goldbergová, Monika $7 xx0054290 $u Institute of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00001735 $t Experimental and clinical cardiology $x 1205-6626 $g Roč. 17, č. 4 (2012), s. 205-209
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23592937 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20130424 $b ABA008
991    __
$a 20140929103104 $b ABA008
999    __
$a ind $b bmc $g 979425 $s 814545
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2012 $b 17 $c 4 $d 205-209 $i 1205-6626 $m Experimental and clinical cardiology $n Exp. Clin. Cardiol. $x MED00001735
GRA    __
$a NS9894 $p MZ0
LZP    __
$a Pubmed-20130424

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace